Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: A multisite randomized clinical trial

Bryan H. King, Kimberly Dukes, Craig L. Donnelly, Linmarie Sikich, James T. McCracken, Lawrence Scahill, Eric Hollander, Joel D. Bregman, Evdokia Anagnostou, Fay Robinson, Lisa Sullivan, Deborah Hirtz

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

IMPORTANCE: The finding of factors that differentially predict the likelihood of response to placebo over that of an active drug could have a significant impact on study design in this population. OBJECTIVE: To identify possible nonspecific, baseline predictors of response to intervention in a large randomized clinical trial of children and adolescents with autism spectrum disorders. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of citalopram hydrobromide for children and adolescents with autism spectrum disorders and prominent repetitive behavior. Baseline data at study entry were examined with respect to final outcome to determine if response predictors could be identified. A total of 149 children and adolescents 5 to 17 years of age (mean [SD] age, 9.4 [3.1] years) from 6 academic centers were randomly assigned to citalopram (n = 73) or placebo (n = 76). Participants had autistic disorder, Asperger syndrome, or pervasive developmental disorder, not otherwise specified; had illness severity ratings that were moderate or more than moderate on the Clinical Global Impression-Severity scale; and scored moderate or more than moderate on compulsive behaviors measured with the modified Children's Yale-Brown Obsessive-Compulsive Scale. INTERVENTIONS: Twelveweeks of treatment with citalopram(10mg/5 mL) or placebo. The mean (SD) maximum dose of citalopramwas 16.5 (6.5)mgby mouth daily (maximum dose, 20mg/d). MAIN OUTCOMES AND MEASURES: A positive response was defined as having a score of at least much improved on the Clinical Global Impression-Improvement scale at week 12. Baseline measures included demographic (sex, age, weight, and pubertal status), clinical, and family measures. Clinical variables included baseline illness severity ratings (the Aberrant Behavior Checklist, the Child and Adolescent Symptom Inventory, the Vineland Adaptive Behavior Scales, the Repetitive Behavior Scale-Revised, and the Children's Yale-Brown Obsessive-Compulsive Scale). Family measures included the Caregiver Strain Questionnaire. RESULTS: Several baseline predictors of response were identified, and a principal component analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) that significantly predicted response at week 12. Specifically, participants in the placebo group were significantly less likely than participants in the citalopram group to respond at week 12 if they entered the study more symptomatic on each of the 3 composite measures, and they were at least 2 times less likely to be responders. CONCLUSIONS AND RELEVANCE: This analysis suggests strategies that may be useful in anticipating and potentially mitigating the nonspecific response in randomized clinical trials of children and adolescents with autism spectrum disorders. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00086645.

Original languageEnglish (US)
Pages (from-to)1045-1052
Number of pages8
JournalJAMA Pediatrics
Volume167
Issue number11
DOIs
StatePublished - 2013

Fingerprint

Citalopram
Randomized Controlled Trials
Placebos
Autistic Disorder
Caregivers
Therapeutics
Compulsive Behavior
Asperger Syndrome
Adolescent Behavior
Psychological Adaptation
Child Behavior
Principal Component Analysis
Checklist
Mouth
Autism Spectrum Disorder
Demography
Outcome Assessment (Health Care)
Weights and Measures
Equipment and Supplies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)

Cite this

Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders : A multisite randomized clinical trial. / King, Bryan H.; Dukes, Kimberly; Donnelly, Craig L.; Sikich, Linmarie; McCracken, James T.; Scahill, Lawrence; Hollander, Eric; Bregman, Joel D.; Anagnostou, Evdokia; Robinson, Fay; Sullivan, Lisa; Hirtz, Deborah.

In: JAMA Pediatrics, Vol. 167, No. 11, 2013, p. 1045-1052.

Research output: Contribution to journalArticle

King, BH, Dukes, K, Donnelly, CL, Sikich, L, McCracken, JT, Scahill, L, Hollander, E, Bregman, JD, Anagnostou, E, Robinson, F, Sullivan, L & Hirtz, D 2013, 'Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: A multisite randomized clinical trial', JAMA Pediatrics, vol. 167, no. 11, pp. 1045-1052. https://doi.org/10.1001/jamapediatrics.2013.2698
King, Bryan H. ; Dukes, Kimberly ; Donnelly, Craig L. ; Sikich, Linmarie ; McCracken, James T. ; Scahill, Lawrence ; Hollander, Eric ; Bregman, Joel D. ; Anagnostou, Evdokia ; Robinson, Fay ; Sullivan, Lisa ; Hirtz, Deborah. / Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders : A multisite randomized clinical trial. In: JAMA Pediatrics. 2013 ; Vol. 167, No. 11. pp. 1045-1052.
@article{f5e63d485d174e548b26a33c8082affc,
title = "Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: A multisite randomized clinical trial",
abstract = "IMPORTANCE: The finding of factors that differentially predict the likelihood of response to placebo over that of an active drug could have a significant impact on study design in this population. OBJECTIVE: To identify possible nonspecific, baseline predictors of response to intervention in a large randomized clinical trial of children and adolescents with autism spectrum disorders. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of citalopram hydrobromide for children and adolescents with autism spectrum disorders and prominent repetitive behavior. Baseline data at study entry were examined with respect to final outcome to determine if response predictors could be identified. A total of 149 children and adolescents 5 to 17 years of age (mean [SD] age, 9.4 [3.1] years) from 6 academic centers were randomly assigned to citalopram (n = 73) or placebo (n = 76). Participants had autistic disorder, Asperger syndrome, or pervasive developmental disorder, not otherwise specified; had illness severity ratings that were moderate or more than moderate on the Clinical Global Impression-Severity scale; and scored moderate or more than moderate on compulsive behaviors measured with the modified Children's Yale-Brown Obsessive-Compulsive Scale. INTERVENTIONS: Twelveweeks of treatment with citalopram(10mg/5 mL) or placebo. The mean (SD) maximum dose of citalopramwas 16.5 (6.5)mgby mouth daily (maximum dose, 20mg/d). MAIN OUTCOMES AND MEASURES: A positive response was defined as having a score of at least much improved on the Clinical Global Impression-Improvement scale at week 12. Baseline measures included demographic (sex, age, weight, and pubertal status), clinical, and family measures. Clinical variables included baseline illness severity ratings (the Aberrant Behavior Checklist, the Child and Adolescent Symptom Inventory, the Vineland Adaptive Behavior Scales, the Repetitive Behavior Scale-Revised, and the Children's Yale-Brown Obsessive-Compulsive Scale). Family measures included the Caregiver Strain Questionnaire. RESULTS: Several baseline predictors of response were identified, and a principal component analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) that significantly predicted response at week 12. Specifically, participants in the placebo group were significantly less likely than participants in the citalopram group to respond at week 12 if they entered the study more symptomatic on each of the 3 composite measures, and they were at least 2 times less likely to be responders. CONCLUSIONS AND RELEVANCE: This analysis suggests strategies that may be useful in anticipating and potentially mitigating the nonspecific response in randomized clinical trials of children and adolescents with autism spectrum disorders. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00086645.",
author = "King, {Bryan H.} and Kimberly Dukes and Donnelly, {Craig L.} and Linmarie Sikich and McCracken, {James T.} and Lawrence Scahill and Eric Hollander and Bregman, {Joel D.} and Evdokia Anagnostou and Fay Robinson and Lisa Sullivan and Deborah Hirtz",
year = "2013",
doi = "10.1001/jamapediatrics.2013.2698",
language = "English (US)",
volume = "167",
pages = "1045--1052",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders

T2 - A multisite randomized clinical trial

AU - King, Bryan H.

AU - Dukes, Kimberly

AU - Donnelly, Craig L.

AU - Sikich, Linmarie

AU - McCracken, James T.

AU - Scahill, Lawrence

AU - Hollander, Eric

AU - Bregman, Joel D.

AU - Anagnostou, Evdokia

AU - Robinson, Fay

AU - Sullivan, Lisa

AU - Hirtz, Deborah

PY - 2013

Y1 - 2013

N2 - IMPORTANCE: The finding of factors that differentially predict the likelihood of response to placebo over that of an active drug could have a significant impact on study design in this population. OBJECTIVE: To identify possible nonspecific, baseline predictors of response to intervention in a large randomized clinical trial of children and adolescents with autism spectrum disorders. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of citalopram hydrobromide for children and adolescents with autism spectrum disorders and prominent repetitive behavior. Baseline data at study entry were examined with respect to final outcome to determine if response predictors could be identified. A total of 149 children and adolescents 5 to 17 years of age (mean [SD] age, 9.4 [3.1] years) from 6 academic centers were randomly assigned to citalopram (n = 73) or placebo (n = 76). Participants had autistic disorder, Asperger syndrome, or pervasive developmental disorder, not otherwise specified; had illness severity ratings that were moderate or more than moderate on the Clinical Global Impression-Severity scale; and scored moderate or more than moderate on compulsive behaviors measured with the modified Children's Yale-Brown Obsessive-Compulsive Scale. INTERVENTIONS: Twelveweeks of treatment with citalopram(10mg/5 mL) or placebo. The mean (SD) maximum dose of citalopramwas 16.5 (6.5)mgby mouth daily (maximum dose, 20mg/d). MAIN OUTCOMES AND MEASURES: A positive response was defined as having a score of at least much improved on the Clinical Global Impression-Improvement scale at week 12. Baseline measures included demographic (sex, age, weight, and pubertal status), clinical, and family measures. Clinical variables included baseline illness severity ratings (the Aberrant Behavior Checklist, the Child and Adolescent Symptom Inventory, the Vineland Adaptive Behavior Scales, the Repetitive Behavior Scale-Revised, and the Children's Yale-Brown Obsessive-Compulsive Scale). Family measures included the Caregiver Strain Questionnaire. RESULTS: Several baseline predictors of response were identified, and a principal component analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) that significantly predicted response at week 12. Specifically, participants in the placebo group were significantly less likely than participants in the citalopram group to respond at week 12 if they entered the study more symptomatic on each of the 3 composite measures, and they were at least 2 times less likely to be responders. CONCLUSIONS AND RELEVANCE: This analysis suggests strategies that may be useful in anticipating and potentially mitigating the nonspecific response in randomized clinical trials of children and adolescents with autism spectrum disorders. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00086645.

AB - IMPORTANCE: The finding of factors that differentially predict the likelihood of response to placebo over that of an active drug could have a significant impact on study design in this population. OBJECTIVE: To identify possible nonspecific, baseline predictors of response to intervention in a large randomized clinical trial of children and adolescents with autism spectrum disorders. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of citalopram hydrobromide for children and adolescents with autism spectrum disorders and prominent repetitive behavior. Baseline data at study entry were examined with respect to final outcome to determine if response predictors could be identified. A total of 149 children and adolescents 5 to 17 years of age (mean [SD] age, 9.4 [3.1] years) from 6 academic centers were randomly assigned to citalopram (n = 73) or placebo (n = 76). Participants had autistic disorder, Asperger syndrome, or pervasive developmental disorder, not otherwise specified; had illness severity ratings that were moderate or more than moderate on the Clinical Global Impression-Severity scale; and scored moderate or more than moderate on compulsive behaviors measured with the modified Children's Yale-Brown Obsessive-Compulsive Scale. INTERVENTIONS: Twelveweeks of treatment with citalopram(10mg/5 mL) or placebo. The mean (SD) maximum dose of citalopramwas 16.5 (6.5)mgby mouth daily (maximum dose, 20mg/d). MAIN OUTCOMES AND MEASURES: A positive response was defined as having a score of at least much improved on the Clinical Global Impression-Improvement scale at week 12. Baseline measures included demographic (sex, age, weight, and pubertal status), clinical, and family measures. Clinical variables included baseline illness severity ratings (the Aberrant Behavior Checklist, the Child and Adolescent Symptom Inventory, the Vineland Adaptive Behavior Scales, the Repetitive Behavior Scale-Revised, and the Children's Yale-Brown Obsessive-Compulsive Scale). Family measures included the Caregiver Strain Questionnaire. RESULTS: Several baseline predictors of response were identified, and a principal component analysis yielded 3 composite measures (disruptive behavior, autism/mood, and caregiver strain) that significantly predicted response at week 12. Specifically, participants in the placebo group were significantly less likely than participants in the citalopram group to respond at week 12 if they entered the study more symptomatic on each of the 3 composite measures, and they were at least 2 times less likely to be responders. CONCLUSIONS AND RELEVANCE: This analysis suggests strategies that may be useful in anticipating and potentially mitigating the nonspecific response in randomized clinical trials of children and adolescents with autism spectrum disorders. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00086645.

UR - http://www.scopus.com/inward/record.url?scp=84888861958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888861958&partnerID=8YFLogxK

U2 - 10.1001/jamapediatrics.2013.2698

DO - 10.1001/jamapediatrics.2013.2698

M3 - Article

C2 - 24061784

AN - SCOPUS:84888861958

VL - 167

SP - 1045

EP - 1052

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 11

ER -